Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 336

1.

Imaging after GliaSite brachytherapy: prognostic MRI indicators of disease control and recurrence.

Kleinberg L, Yoon G, Weingart JD, Parisi M, Olivi A, Detorie NA, Chan TA.

Int J Radiat Oncol Biol Phys. 2009 Dec 1;75(5):1385-91. doi: 10.1016/j.ijrobp.2008.12.074. Epub 2009 Apr 23.

PMID:
19394153
2.

Treatment of recurrent glioblastoma multiforme with GliaSite brachytherapy.

Chan TA, Weingart JD, Parisi M, Hughes MA, Olivi A, Borzillary S, Alahakone D, Detorie NA, Wharam MD, Kleinberg L.

Int J Radiat Oncol Biol Phys. 2005 Jul 15;62(4):1133-9.

PMID:
15990019
3.

GliaSite brachytherapy boost as part of initial treatment of glioblastoma multiforme: a retrospective multi-institutional pilot study.

Welsh J, Sanan A, Gabayan AJ, Green SB, Lustig R, Burri S, Kwong E, Stea B.

Int J Radiat Oncol Biol Phys. 2007 May 1;68(1):159-65. Epub 2007 Feb 27.

PMID:
17331666
4.

GliaSite brachytherapy for treatment of recurrent malignant gliomas: a retrospective multi-institutional analysis.

Gabayan AJ, Green SB, Sanan A, Jenrette J, Schultz C, Papagikos M, Tatter SP, Patel A, Amin P, Lustig R, Bastin KT, Watson G, Burri S, Stea B.

Neurosurgery. 2006 Apr;58(4):701-9; discussion 701-9. Erratum in: Neurosurgery. 2006 Oct;59(4):821.

PMID:
16575334
5.

Permanent iodine-125 interstitial implants for the treatment of recurrent glioblastoma multiforme.

Patel S, Breneman JC, Warnick RE, Albright RE Jr, Tobler WD, van Loveren HR, Tew JM Jr.

Neurosurgery. 2000 May;46(5):1123-8; discussion 1128-30.

PMID:
10807244
6.

The role of dose escalation with intracavitary brachytherapy in the treatment of localized CNS malignancies: outcomes and toxicities of a prospective study.

Wernicke AG, Sherr DL, Schwartz TH, Pannullo SC, Stieg PE, Boockvar JA, Moliterno JA, Ivanidze J, Trichter S, Sabbas AM, Parashar B, Nori D.

Brachytherapy. 2010 Jan-Mar;9(1):91-9. doi: 10.1016/j.brachy.2009.06.005. Epub 2009 Oct 21.

PMID:
19850535
7.

Feasibility and safety of GliaSite brachytherapy in treatment of CNS tumors following neurosurgical resection.

Wernicke AG, Sherr DL, Schwartz TH, Pannullo SC, Stieg PE, Boockvar JA, Ivanidze J, Moliterno JA, Parashar B, Trichter S, Sabbas AM, Nori D.

J Cancer Res Ther. 2010 Jan-Mar;6(1):65-74. doi: 10.4103/0973-1482.63547.

8.

CT and MR imaging after placement of the GliaSite radiation therapy system to treat brain tumor: initial experience.

Matheus MG, Castillo M, Ewend M, Smith JK, Knock L, Cush S, Morris DE.

AJNR Am J Neuroradiol. 2004 Aug;25(7):1211-7.

9.

Longitudinal magnetic resonance imaging features of glioblastoma multiforme treated with radiotherapy with or without brachytherapy.

Aiken AH, Chang SM, Larson D, Butowski N, Cha S.

Int J Radiat Oncol Biol Phys. 2008 Dec 1;72(5):1340-6. doi: 10.1016/j.ijrobp.2008.02.078. Epub 2008 Jun 4.

PMID:
18538496
10.

Phase I trial of gross total resection, permanent iodine-125 brachytherapy, and hyperfractionated radiotherapy for newly diagnosed glioblastoma multiforme.

Chen AM, Chang S, Pouliot J, Sneed PK, Prados MD, Lamborn KR, Malec MK, McDermott MW, Berger MS, Larson DA.

Int J Radiat Oncol Biol Phys. 2007 Nov 1;69(3):825-30. Epub 2007 May 23.

PMID:
17512132
11.

3D MRSI for resected high-grade gliomas before RT: tumor extent according to metabolic activity in relation to MRI.

Pirzkall A, Li X, Oh J, Chang S, Berger MS, Larson DA, Verhey LJ, Dillon WP, Nelson SJ.

Int J Radiat Oncol Biol Phys. 2004 May 1;59(1):126-37.

PMID:
15093908
12.

Survival and functional status after resection of recurrent glioblastoma multiforme.

Barker FG 2nd, Chang SM, Gutin PH, Malec MK, McDermott MW, Prados MD, Wilson CB.

Neurosurgery. 1998 Apr;42(4):709-20; discussion 720-3.

PMID:
9574634
13.

Effects of iodine-125 brachytherapy on the proliferative capacity and histopathological features of glioblastoma recurring after initial therapy.

Siddiqi SN, Provias J, Laperriere N, Bernstein M.

Neurosurgery. 1997 May;40(5):910-7; discussion 917-8.

PMID:
9149248
14.

Brachytherapy of glioblastoma recurring in previously irradiated territory: predictive value of tumor volume.

Simon JM, Cornu P, Boisserie G, Hasboun D, Tep B, Hardiman C, Valery CA, Delattre JY, Dormont D, Baillet F, Mazeron JJ.

Int J Radiat Oncol Biol Phys. 2002 May 1;53(1):67-74.

PMID:
12007943
15.

Treatment of recurrent high-grade gliomas with GliaSite brachytherapy: a prospective mono-institutional Italian experience.

Gobitti C, Borsatti E, Arcicasa M, Roncadin M, Franchin G, Minatel E, Skrap M, Zanotti B, Tuniz F, Cimitan M, Capra E, Drigo A, Trovò MG.

Tumori. 2011 Sep-Oct;97(5):614-9. doi: 10.1700/989.10721.

16.
17.

Prognostic factors in recurrent glioblastoma multiforme and anaplastic astrocytoma treated with selective intra-arterial chemotherapy.

Chow KL, Gobin YP, Cloughesy T, Sayre JW, Villablanca JP, Viñuela F.

AJNR Am J Neuroradiol. 2000 Mar;21(3):471-8.

18.

Extent of resection and survival in glioblastoma multiforme: identification of and adjustment for bias.

Stummer W, Reulen HJ, Meinel T, Pichlmeier U, Schumacher W, Tonn JC, Rohde V, Oppel F, Turowski B, Woiciechowsky C, Franz K, Pietsch T; ALA-Glioma Study Group.

Neurosurgery. 2008 Mar;62(3):564-76; discussion 564-76. doi: 10.1227/01.neu.0000317304.31579.17.

PMID:
18425006
19.

[Prediction of clinical course of glioblastomas by MRI during radiotherapy].

Leitzen C, Schild HH, Bungart B, Herrlinger U, Lütter C, Müdder T, Wilhelm-Buchstab T, Schüller H.

Strahlenther Onkol. 2010 Dec;186(12):681-6. doi: 10.1007/s00066-010-2156-8. Epub 2010 Nov 29. German.

PMID:
21221885
20.

Survival following stereotactic radiosurgery for newly diagnosed and recurrent glioblastoma multiforme: a multicenter experience.

Villavicencio AT, Burneikiene S, Romanelli P, Fariselli L, McNeely L, Lipani JD, Chang SD, Nelson EL, McIntyre M, Broggi G, Adler JR Jr.

Neurosurg Rev. 2009 Oct;32(4):417-24. doi: 10.1007/s10143-009-0212-6. Epub 2009 Jul 25.

PMID:
19633875

Supplemental Content

Support Center